• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿科药代动力学数据:对儿童环境风险评估的影响

Pediatric pharmacokinetic data: implications for environmental risk assessment for children.

作者信息

Ginsberg Gary, Hattis Dale, Miller Richard, Sonawane Babasaheb

机构信息

Connecticut Department of Public Health, Hartford, Connecticut 06134, USA.

出版信息

Pediatrics. 2004 Apr;113(4 Suppl):973-83.

PMID:15060190
Abstract

Pharmacology and toxicology share a common interest in pharmacokinetic data, especially as it is available in pediatric populations. These data have been critical to the clinical pharmacologist for many years in designing age-specific dosing regimens. Now they are being used increasingly by toxicologists to understand the ontogeny of physiologic parameters that may affect the metabolism and clearance of environmental toxicants. This article reviews a wide range of physiologic and metabolic factors that are present in utero and in early postnatal life and that can affect the internal dose of an absorbed chemical and its metabolites. It also presents a child/adult pharmacokinetic database that includes data for 45 therapeutic drugs organized into specific children's age groupings and clearance pathways. Analysis of these data suggests that substantial child/adult differences in metabolism and clearance are likely for a variety of drugs and environmental chemicals in the early postnatal period. These results are also relevant to in utero exposures, where metabolic systems are even more immature, but exposures are greatly modified by the maternal system and placental metabolism. The implications of these child/adult differences for assessing children's risks from environmental toxicants is discussed with special focus on physiologically based pharmacokinetic modeling strategies that could simulate children's abilities to metabolize and eliminate chemicals at various developmental stages.

摘要

药理学和毒理学都对药代动力学数据有着共同的兴趣,尤其是儿科人群中的此类数据。多年来,这些数据对于临床药理学家设计针对特定年龄的给药方案至关重要。现在,毒理学家越来越多地利用这些数据来了解可能影响环境毒物代谢和清除的生理参数的个体发育情况。本文综述了子宫内和出生后早期存在的多种生理和代谢因素,这些因素会影响吸收的化学物质及其代谢产物的体内剂量。文章还展示了一个儿童/成人药代动力学数据库,其中包含45种治疗药物的数据,这些数据按照特定的儿童年龄分组和清除途径进行了整理。对这些数据的分析表明,出生后早期,多种药物和环境化学物质在代谢和清除方面很可能存在显著的儿童/成人差异。这些结果也与子宫内暴露相关,在子宫内,代谢系统更为不成熟,但暴露情况会受到母体系统和胎盘代谢的极大影响。本文讨论了这些儿童/成人差异对于评估儿童环境毒物风险的意义,特别关注基于生理学的药代动力学建模策略,该策略可模拟儿童在不同发育阶段代谢和消除化学物质的能力。

相似文献

1
Pediatric pharmacokinetic data: implications for environmental risk assessment for children.儿科药代动力学数据:对儿童环境风险评估的影响
Pediatrics. 2004 Apr;113(4 Suppl):973-83.
2
Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants.在评估儿童对环境毒物的风险时纳入儿童与成人之间的药代动力学差异。
Toxicol Appl Pharmacol. 2004 Jul 15;198(2):164-83. doi: 10.1016/j.taap.2003.10.010.
3
Utilization of juvenile animal studies to determine the human effects and risks of environmental toxicants during postnatal developmental stages.利用幼年动物研究来确定产后发育阶段环境毒物对人类的影响和风险。
Birth Defects Res B Dev Reprod Toxicol. 2004 Oct;71(5):303-20. doi: 10.1002/bdrb.20020.
4
Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents.新生儿和成人中咖啡因和茶碱基于生理的药代动力学(PBPK)建模:对评估儿童环境暴露风险的启示
J Toxicol Environ Health A. 2004 Feb 27;67(4):297-329. doi: 10.1080/15287390490273550.
5
Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents).利用动物研究来确定环境毒物(药物、化学物质和物理因子)的影响及对人类的风险。
Pediatrics. 2004 Apr;113(4 Suppl):984-95.
6
Role of biokinetics in risk assessment of drugs and chemicals in children.
Regul Toxicol Pharmacol. 2004 Jun;39(3):282-309. doi: 10.1016/j.yrtph.2004.02.006.
7
Optimizing pediatric dosing: a developmental pharmacologic approach.优化儿科用药剂量:一种发育药理学方法。
Pharmacotherapy. 2009 Jun;29(6):680-90. doi: 10.1592/phco.29.6.680.
8
Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop report.儿科人群中化学品和药物的风险评估:研讨会报告
Regul Toxicol Pharmacol. 2005 Jun;42(1):83-95. doi: 10.1016/j.yrtph.2005.01.005. Epub 2005 Mar 2.
9
Applicability of the principles of developmental pharmacology to the study of environmental toxicants.
Pediatrics. 2004 Apr;113(4 Suppl):969-72.
10
Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.转基因植物及其衍生食品和饲料的安全性与营养评估:动物饲养试验的作用
Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13.

引用本文的文献

1
Anthropogenic influence on groundwater metal toxicity and risk to human health assessment in Umaria coalfield of Madhya Pradesh, India.印度中央邦乌玛利亚煤田人为活动对地下水金属毒性及人体健康风险评估的影响
Sci Rep. 2025 Apr 8;15(1):12007. doi: 10.1038/s41598-025-88783-x.
2
Advancing understanding of human variability through toxicokinetic modeling, in vitro-in vivo extrapolation, and new approach methodologies.通过毒代动力学建模、体外-体内外推和新方法学来提高对人类变异性的认识。
Hum Genomics. 2024 Nov 21;18(1):129. doi: 10.1186/s40246-024-00691-9.
3
Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats.
新型细菌拓扑异构酶抑制剂 gepotidacin 显示在幼年大鼠中不存在氟喹诺酮类关节病。
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0048322. doi: 10.1128/aac.00483-22. Epub 2022 Oct 18.
4
A population physiologically-based pharmacokinetic model to characterize antibody disposition in pediatrics and evaluation of the model using infliximab.建立群体生理药代动力学模型以描述儿科人群中抗体的处置特征,并采用英夫利昔单抗对该模型进行评估。
Br J Clin Pharmacol. 2022 Jan;88(1):290-302. doi: 10.1111/bcp.14963. Epub 2021 Jul 19.
5
Early-life exposure to aluminum and fine motor performance in infants: a longitudinal study.婴儿早期接触铝与精细运动表现:一项纵向研究
J Expo Sci Environ Epidemiol. 2021 Mar;31(2):248-256. doi: 10.1038/s41370-021-00294-9. Epub 2021 Feb 17.
6
How to Conduct Clinical Trials in Children: A Tutorial.如何在儿童中开展临床试验:教程。
Clin Transl Sci. 2019 May;12(3):218-230. doi: 10.1111/cts.12615. Epub 2019 Mar 18.
7
Development of growth equations from longitudinal studies of body weight and height in the full term and preterm neonate: From birth to four years postnatal age.从足月和早产儿的体重和身高纵向研究中制定生长方程:从出生到出生后四年。
Birth Defects Res. 2018 Jul 3;110(11):916-932. doi: 10.1002/bdr2.1214. Epub 2018 Mar 14.
8
A Review of the Field on Children's Exposure to Environmental Contaminants: A Risk Assessment Approach.儿童接触环境污染物领域综述:一种风险评估方法
Int J Environ Res Public Health. 2017 Mar 4;14(3):265. doi: 10.3390/ijerph14030265.
9
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients.评估单剂量头孢他啶-阿维巴坦在住院儿科患者中的药代动力学特征、安全性和耐受性的I期研究
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6252-9. doi: 10.1128/AAC.00862-16. Print 2016 Oct.
10
Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model.发育中的哥廷根小型猪的器官数据:建立幼年生理药代动力学(PBPK)模型的初步步骤。
J Pharmacokinet Pharmacodyn. 2016 Apr;43(2):179-90. doi: 10.1007/s10928-015-9463-8. Epub 2015 Dec 19.